Scientific Projects
The complete diploid reference genome of RPE-1 identifies human phased epigenetic landscapes
A huge scientific milestone innovating the understanding of the human genome was made possible by the contribution of Dante Genomics.
The creation of the world's first fully diploid human genomes represents a key step toward a more accurate representation of the human genome: an incredible discovery that revolutionizes human health.
- World's first complete human diploid genome of a widely used laboratory cell line as a matched genomic reference.
- A historic achievement that provides more reliable results with this model and obtains a high-precision characterization of the human genome.
- This will support scientific discoveries and eventually improve human life
Dante genomics has been the main strategic partner in providing access to the most advanced long-reds sequencing technologies.
This Research projects represents a key step forward towards a more accurate use of human reference genomes and will impact on the global approach to health care and future genomic studies.
Large-scale DNA sequencing identifies rare variants associated with Systemic Lupus Erythematosus susceptibility in known risk genes
Dante Genomics has proudly collaborated on a groundbreaking study on Systemic Lupus Erythematosus (SLE) with prestigious universities in Italy and the US.
Our team worked tirelessly to identify rare genetic variants linked to this disease, shedding light on its pathogenic mechanisms.
Through cutting-edge Whole Genome Sequencing Analysis powered by Dante Genomics, we are unlocking new possibilities for the diagnosis and treatment of genetic diseases once thought incurable.
Our research is paving the way for innovative approaches to understanding and combating rare diseases.
A tiered strategy for variant selection in patients with epilepsy
Introduction
Epilepsy is one of the most common neurological conditions often characterized by recurrent episodes of seizures. The etiology is heterogeneous, however genetic factors are thought to play a major role. In the past decade, Next Generation Sequencing (NGS) resulted in the identification of novel sequence variants associated with susceptibility to epilepsy. This set of new knowledge has already been used to identify personalized therapies for affected patients.
A computational approach to design a COVID-19 vaccine against a predicted SARS-CoV-2 variant: high immunogenicity, efficacy and safety of DELLERA vaccine.
Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an enveloped positive-sense single-stranded RNA (ssRNA) virus of the Betacoronavirus genus which has spread worldwide and causing 6,259,945 deaths since its first identification in 2019. Even if the development of coronavirus disease 2019 (COVID-19) vaccines has proceeded at an extremely rapid pace due to an unprecedent acceleration of the traditional vaccine development, achieving global vaccine coverage remains a major hurdle due to the continue evolution and selection of vaccine escape variants under immune selective pressures. Therefore the tireless development of new candidate vaccines remains critical. In the fight against the OVID-19, the use of computational biology tools was found to be crucial for different tasks.
Novel siRNA-based therapeutic approach for Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS)
Introduction
MMIHS is a rare form of functional intestinal obstruction in the newborn characterized by megacystis, microcolon, and intestinal dysmotility. A classic feature of MMIHS is represented by ACTG2 mutations that can be both inherited in an autosomal dominant manner or occur as de novo events during oogenesis, spermatogenesis, or early embryonic development. ACTG2 encodes y-2 enteric actin and its mutations disrupt actin polymerization leading to impaired contraction of intestinal smooth muscle cells. Even though survival has improved in recent years, MMIHS is a condition that requires invasive palliative treatments.